You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Manhattan-based lab will scale its capacity to process 20,000 tests per day by November and provide results dedicated to the city.
The US National Institutes of Health is urging clinical trial sponsors to add in years of missing data, according to Stat News.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
In PLOS this week: FANCJ mutations linked to increased sensitivity to certain drugs, host genetic factors influence wound microbiomes, and more.
New York University researchers find that more average- and low-achieving men pursue physics, engineering, and computer science majors than higher-scoring women.
The paper, which is not peer-reviewed, said that use of the test as a first-step screening tool would require confirmation of more than 80 percent of its results.
Two analyses indicate that SARS-CoV-2 began circulating in New York in mid-February, coming from Europe.
Researchers at Mount Sinai, NYU School of Medicine, and Weill Cornell Medicine sequenced hundreds of SARS-CoV-2 genomes from NYC patients for phylogenetic analyses.
Researchers found that small-molecule inhibitors targeting oncogenic signal transduction or epigenetic regulation can alter specific 3D interactions in leukemia.
The screening platform, which uses the Cas13 nuclease to target RNA instead of DNA, can be used to design guide RNAs for CRISPR research.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
Time magazine looks into how liquid biopsies are changing cancer care.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.